{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:55:06Z","timestamp":1784858106636,"version":"3.55.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.clinbiochem.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T10:55:49Z","timestamp":1634640949000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Laboratory biomarkers of Multiple Sclerosis (MS)"],"prefix":"10.1016","volume":"99","author":[{"given":"Borros","family":"Arneth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0005","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/1744666X.2015.991315","article-title":"Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future","volume":"11","author":"Raphael","year":"2015","journal-title":"Expert Rev Clin Immunol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2020.574133","article-title":"Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review","volume":"7","author":"Porter","year":"2020","journal-title":"Front Mol Biosci."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a029058","article-title":"Biomarkers in Multiple Sclerosis","volume":"9","author":"Paul","year":"2019","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clim.2015.06.015","article-title":"Biomarkers in multiple sclerosis","volume":"161","author":"Housley","year":"2015","journal-title":"Clin Immunol Orlando Fla."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874226201909010001","article-title":"Biomarkers of Multiple Sclerosis","volume":"9","author":"Pastare","year":"2019","journal-title":"Open Immunol J."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.msard.2018.07.030","article-title":"Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter?","volume":"25","author":"Pryce","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/296184","article-title":"Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments","volume":"2015","author":"Bonnan","year":"2015","journal-title":"Mult Scler Int."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/340508","article-title":"Biomarkers in Multiple Sclerosis: An Up-to-Date Overview","volume":"2013","author":"Katsavos","year":"2013","journal-title":"Mult Scler Int."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaut.2014.01.022","article-title":"The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review","volume":"48\u201349","author":"Karussis","year":"2014","journal-title":"J Autoimmun."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.10.004_b0055","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.10.004_b0060","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","article-title":"Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude","volume":"84","author":"Dobson","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.10.004_b0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","article-title":"The utility of cerebrospinal fluid analysis in patients with multiple sclerosis","volume":"9","author":"Stangel","year":"2013","journal-title":"Nat Rev Neurol."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pneurobio.2016.04.009","article-title":"The pathophysiological role of astrocytic endothelin-1","volume":"144","author":"Hostenbach","year":"2016","journal-title":"Prog Neurobiol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/cshperspect.a028969","article-title":"Magnetic Resonance Imaging in Multiple Sclerosis","volume":"8","author":"Hemond","year":"2018","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"12","key":"10.1016\/j.clinbiochem.2021.10.004_b0085","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archneurol.2011.914","article-title":"Magnetic resonance techniques in multiple sclerosis: the present and the future","volume":"68","author":"Filippi","year":"2011","journal-title":"Arch Neurol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","article-title":"The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature","volume":"264","author":"Jarius","year":"2017","journal-title":"J Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-018-1018-3","article-title":"The MRZ reaction helps to distinguish rheumatologic disorders with central nervous involvement from multiple sclerosis","volume":"18","author":"Hottenrott","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3410\/M5-4","article-title":"Polyclonal free light chains: a biomarker of inflammatory disease or treatment target?","volume":"5","author":"Brebner","year":"2013","journal-title":"F1000 Med Rep."},{"issue":"4","key":"10.1016\/j.clinbiochem.2021.10.004_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8040446","article-title":"K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up","volume":"8","author":"Crespi","year":"2019","journal-title":"J Clin Med."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.10.004_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0089945","article-title":"Kappa free light chains: diagnostic and prognostic relevance in MS and CIS","volume":"9","author":"Presslauer","year":"2014","journal-title":"PloS One."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/2303857","article-title":"Free Light Chains and Intrathecal B Cells Activity in Multiple Sclerosis: A Prospective Study and Meta-Analysis","volume":"2016","author":"Passerini","year":"2016","journal-title":"Mult Scler Int."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0120","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/brain\/awaa458","article-title":"Subclinical anterior optic pathway involvement in early multiple sclerosis and clinically isolated syndromes","volume":"144","author":"Pisa","year":"2021","journal-title":"Brain J Neurol."},{"issue":"23\u201324","key":"10.1016\/j.clinbiochem.2021.10.004_b0125","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cca.2012.07.007","article-title":"High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis","volume":"413","author":"Villar","year":"2012","journal-title":"Clin Chim Acta Int J Clin Chem."},{"issue":"6","key":"10.1016\/j.clinbiochem.2021.10.004_b0130","first-page":"1","article-title":"Cerebrospinal Fluid Analysis in Multiple Sclerosis Diagnosis: An Update","volume":"55","author":"Lo Sasso","year":"2019","journal-title":"Med Kaunas Lith."},{"issue":"11","key":"10.1016\/j.clinbiochem.2021.10.004_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0166556","article-title":"Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting","volume":"11","author":"Zeman","year":"2016","journal-title":"PloS One."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00641","article-title":"CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort","volume":"10","author":"Senel","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-77029-7","article-title":"Intrathecal kappa free light chains as markers for multiple sclerosis","volume":"10","author":"Vecchio","year":"2020","journal-title":"Sci Rep."},{"issue":"9","key":"10.1016\/j.clinbiochem.2021.10.004_b0150","first-page":"1","article-title":"Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis","volume":"14","author":"Romme Christensen","year":"2012","journal-title":"J Neuroinflammation."},{"issue":"1\u20132","key":"10.1016\/j.clinbiochem.2021.10.004_b0155","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jneuroim.2012.04.015","article-title":"Serum level of interleukin-6 in Chinese patients with multiple sclerosis","volume":"249","author":"Chen","year":"2012","journal-title":"J Neuroimmunol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10753-012-9517-7","article-title":"Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases?","volume":"36","author":"Karimabad","year":"2013","journal-title":"Inflammation."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0165","doi-asserted-by":"crossref","unstructured":"Schneider R, Mohebiany AN, Ifergan I, Beauseigle D, Duquette P. Prat A, Arbour N. B cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. J Immunol Baltim Md 1950. 2011 Oct 15. 187(8). 4119\u201328.","DOI":"10.4049\/jimmunol.1100885"},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/436764","article-title":"Cytokines as Biomarkers of Treatment Response to IFN \u03b2 in Relapsing-Remitting Multiple Sclerosis","volume":"2014","author":"Dimisianos","year":"2014","journal-title":"Mult Scler Int."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.10.004_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135434","article-title":"Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation","volume":"10","author":"Mouzaki","year":"2015","journal-title":"PloS One."},{"issue":"9","key":"10.1016\/j.clinbiochem.2021.10.004_b0180","first-page":"1","article-title":"CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation","volume":"16","author":"Kowarik","year":"2012","journal-title":"J Neuroinflammation."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"283","key":"10.1016\/j.clinbiochem.2021.10.004_b0190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneuroim.2015.04.011","article-title":"Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis","volume":"15","author":"Ferraro","year":"2015","journal-title":"J Neuroimmunol."},{"issue":"6","key":"10.1016\/j.clinbiochem.2021.10.004_b0195","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann Neurol."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.10.004_b0200","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain J Neurol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2021.10.004_b0205","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1177\/1352458517732844","article-title":"Fluid biomarker and electrophysiological outcome measures for progressive MS trials","volume":"23","author":"Barro","year":"2017","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458518765666","article-title":"Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis","volume":"25","author":"Siller","year":"2019","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"22","key":"10.1016\/j.clinbiochem.2021.10.004_b0215","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","article-title":"Monitoring disease activity in multiple sclerosis using serum neurofilament light protein","volume":"89","author":"Novakova","year":"2017","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.10.004_b0220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/ana.23591","article-title":"Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis","volume":"72","author":"Mowry","year":"2012","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.10.004_b0225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ene.12844","article-title":"Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection","volume":"23","author":"Mowry","year":"2016","journal-title":"Eur J Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2011.11.006","article-title":"CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients","volume":"38","author":"Broux","year":"2012","journal-title":"J Autoimmun."},{"issue":"287","key":"10.1016\/j.clinbiochem.2021.10.004_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaa8038","article-title":"Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis","volume":"7","author":"Cao","year":"2015","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0240","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.09.010","article-title":"Clinical utility of anti-MOG antibody testing in a Danish cohort","volume":"26","author":"Papp","year":"2018","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0245","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"10.1016\/j.clinbiochem.2021.10.004_b0250","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s00115-018-0607-0","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"89","author":"Jarius","year":"2018","journal-title":"Nervenarzt."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1674-2","article-title":"Molecular biomarkers in multiple sclerosis","volume":"16","author":"Ziemssen","year":"2019","journal-title":"J Neuroinflammation."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.10.004_b0260","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/jamaneurol.2018.1055","article-title":"Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity?","volume":"75","author":"Weber","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286418762083","article-title":"Defining distinct features of anti-MOG antibody associated central nervous system demyelination","volume":"11","author":"Weber","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/SNI-4-2019","article-title":"Anti-John Cunningham virus antibody index levels in multiple sclerosis patients treated with rituximab, fingolimod, and dimethyl fumarate","volume":"10","author":"Farley","year":"2019","journal-title":"Surg Neurol Int."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0275","first-page":"1","article-title":"Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab","volume":"5","author":"Antoniol","year":"2014","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.clinbiochem.2021.10.004_b0280","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458513477925","article-title":"Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort","volume":"19","author":"Olsson","year":"2013","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"7","key":"10.1016\/j.clinbiochem.2021.10.004_b0285","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"6","key":"10.1016\/j.clinbiochem.2021.10.004_b0290","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol."},{"issue":"4","key":"10.1016\/j.clinbiochem.2021.10.004_b0295","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1212\/WNL.0000000000006810","article-title":"Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge","volume":"92","author":"Gasperini","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/262350","article-title":"Outcome measures in relapsing-remitting multiple sclerosis: capturing disability and disease progression in clinical trials","volume":"2014","author":"Lavery","year":"2014","journal-title":"Mult Scler Int."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0305","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/1756285613484079","article-title":"Magnetic resonance monitoring of lesion evolution in multiple sclerosis","volume":"6","author":"Rovira","year":"2013","journal-title":"Ther Adv Neurol Disord."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0310","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/1754-9485.12498","article-title":"Imaging in multiple sclerosis: A new spin on lesions","volume":"60","author":"Bou Fakhredin","year":"2016","journal-title":"J Med Imaging Radiat Oncol."},{"issue":"12","key":"10.1016\/j.clinbiochem.2021.10.004_b0315","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S1474-4422(12)70230-2","article-title":"Measurement and clinical effect of grey matter pathology in multiple sclerosis","volume":"11","author":"Geurts","year":"2012","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0320","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neuroimage.2011.02.041","article-title":"Magnetisation transfer ratio in optic neuritis is associated with axonal loss, but not with demyelination","volume":"56","author":"Klistorner","year":"2011","journal-title":"NeuroImage."},{"issue":"66","key":"10.1016\/j.clinbiochem.2021.10.004_b0330","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuroimage.2012.10.059","article-title":"Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis","volume":"1","author":"Brown","year":"2013","journal-title":"NeuroImage."},{"issue":"2","key":"10.1016\/j.clinbiochem.2021.10.004_b0335","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrg2936","article-title":"Gene silencing by microRNAs: contributions of translational repression and mRNA decay","volume":"12","author":"Huntzinger","year":"2011","journal-title":"Nat Rev Genet."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0340","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1007\/s12035-013-8400-3","article-title":"MicroRNAs in the brain: it\u2019s regulatory role in neuroinflammation","volume":"47","author":"Thounaojam","year":"2013","journal-title":"Mol Neurobiol."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0345","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.3390\/ijms14034375","article-title":"Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis","volume":"14","author":"Ridolfi","year":"2013","journal-title":"Int J Mol Sci."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0350","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23860","article-title":"Hippocampal demyelination and memory dysfunction are associated with increased levels of the neuronal microRNA miR-124 and reduced AMPA receptors","volume":"73","author":"Dutta","year":"2013","journal-title":"Ann Neurol."},{"issue":"7","key":"10.1016\/j.clinbiochem.2021.10.004_b0355","first-page":"1","article-title":"Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-\u03b2","volume":"17","author":"De Felice","year":"2014","journal-title":"BMC Med Genomics."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0360","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1352458513496343","article-title":"Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing","volume":"20","author":"Keller","year":"2014","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"9","key":"10.1016\/j.clinbiochem.2021.10.004_b0365","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1177\/1352458515613641","article-title":"Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis","volume":"22","author":"Ahlbrecht","year":"2016","journal-title":"Mult Scler Houndmills Basingstoke Engl."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.10.004_b0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000219","article-title":"Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.10.004_b0375","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1007\/s11033-011-1441-7","article-title":"Circulating microRNAs involved in multiple sclerosis","volume":"39","author":"Siegel","year":"2012","journal-title":"Mol Biol Rep."},{"issue":"1","key":"10.1016\/j.clinbiochem.2021.10.004_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12987-016-0049-7","article-title":"The MRZ reaction in primary progressive multiple sclerosis","volume":"14","author":"Hottenrott","year":"2017","journal-title":"Fluids Barriers CNS."},{"issue":"9","key":"10.1016\/j.clinbiochem.2021.10.004_b0385","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/jnnp-2018-319190","article-title":"Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case-control studies","volume":"90","author":"Martin","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"10","key":"10.1016\/j.clinbiochem.2021.10.004_b0390","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","article-title":"Blood neurofilament light chain as a biomarker of MS disease activity and treatment response","volume":"92","author":"Kuhle","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.clinbiochem.2021.10.004_b0395","first-page":"19","article-title":"Biomarkers of multiple sclerosis: current findings","volume":"7","author":"Harris","year":"2017","journal-title":"Degener Neurol Neuromuscul Dis."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:58:07Z","timestamp":1757865487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912021002757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":79,"alternative-id":["S0009912021002757"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.10.004","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory biomarkers of Multiple Sclerosis (MS)","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}